Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 601–700 of 2,039
Hansford, R., Buller, S. A., Tsang, A. H. K., Benoit, S., Roberts, A. G., Erskine, E., Brown, T., Pirro, V., Reimann, F., Harada, N., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.07.009 · Cited by 23
Fahim, S. A., Attia, Y. M., Messiha, A. A., Nabawy, A. Y., Refaat, F., & El-Maadawy, W. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118731 · Cited by 22
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02465-x · Cited by 18
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22
“doses was significantly larger when compared with active controls like insulin glargine (SURPASS-4), insulin degludec (SURPASS-3) or semaglutide 1 mg (SURPASS-2) [9-11].”
BackgroundMethodInfluentialSohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 17
Self-citationLyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 19
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
MacIsaac, R. J., Deed, G., dʼEmden, M. C., Ekinci, E. I., HOCKING, S. L., Sumithran, P., & Rasalam, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01475-5 · Cited by 17
“In SURPASS-2, reductions in triglycerides and VLDL-C with tirzepatide (all doses) exceeded those seen with semaglutide 1 mg [9].”
BackgroundInfluentialMuzurović, E. M., Yumuk, V., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108647 · Cited by 15
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 28
Samarasinghe, S., Oštarijaš, E., Long, M. J., Erridge, S., Purkayastha, S., Dimitriadis, G. K., & Miras, A. D. (2024) · Obesity Reviews · doi:10.1111/obr.13744 · Cited by 20
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos, R. D., & Stein, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00515-4 · Cited by 18
“Phase III studies showed a significant reduction in HbA1c levels and body weight in patients with T2DM [44, 45].”
BackgroundApproach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155531 · Cited by 16
Tirzepatide: a new low for bodyweight and blood glucose
Bailey, C. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00217-5 · Cited by 18
Nowak, M., Nowak, W., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0029 · Cited by 27
Cai, C., Woolhandler, S., McCormick, D., Himmelstein, D. U., Himmelstein, J., Schrier, E., & Dickman, S. L. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07428-1 · Cited by 14
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Nowak, K., Łupina, K., Romac, A., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251322002 · Cited by 21
“45 Similarly, retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, has shown impressive efficacy in a phase 2 clinical trial for MASLD.”
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
Velji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 23
Kumar, N., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac276 · Cited by 14
Razzaki, T. S., Weiner, A., & Shukla, A. P. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s328056 · Cited by 16
“There were 4 cases in each tirzepatide dose group with cholelithiasis as compared to 2 cases in the semaglutide group.(26) There were no reported cases of medullary thyroid cancer in any of the tirzepatide trials.”
InfluentialKushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
Ge, D., Foer, D., & Cahill, K. N. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00211-x · Cited by 14
“Two recent phase 3 multicenter randomized trials in adults with obesity showed that tirzepatide, a novel dual gastric inhibitory peptide\GLP-1R agonist, caused substantial weight loss in patients who failed to lose weight via dietary changes and noninferior and superior glycemic control compared to semaglutide in thos…”
BackgroundThe Oral Delivery System of Modified GLP-1 by Probiotics for T2DM
Wang, Q., Guo, H., Mao, W., Qian, X., & Liu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041202 · Cited by 18
Tirzepatide and potential use for metabolically healthy obesity
Çöpür, S., Tanrıöver, C., Yavuz, F., Tuttle, K. R., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.012 · Cited by 18
Burkett, W. C., Clontz, A. D., Keku, T. O., & Bae-Jump, V. L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189000 · Cited by 24
Galindo, R. J., Uppal, T. S., McCoy, R. G., Umpierrez, G. E., & Ali, M. K. (2023) · Obesity · doi:10.1002/oby.23869 · Cited by 14
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
Holst, J. J., Madsbad, S., Bojsen-Møller, K. N., Dirksen, C., & Svane, M. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171199 · Cited by 18
“It is of great current interest because of the unprecedented effects of tirzepatide, an agonist of both the GLP-1 and the GIP receptor, on food intake and body weight (up to 25% weight loss) as well as type 2 diabetes, with apparent remission observed in > 50% of type 2 diabetes patients [53,54].”
BackgroundGLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 18
“…evaluated on a 7-point daily glucose profile demonstrated better control at all points of the glycemic profile compared to semaglutide 1 mg [3]; on the other hand, the comparison with insulin degludec showed that although insulin, titrated during the study, obtained a better result on…”
BackgroundMethodInfluentialSeetharaman, R., Pawar, S. R., & Advani, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15100 · Cited by 17
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.43 · Cited by 19
“The SURPASS programme investigating tirzepatide, a once-weekly dual GIP/GLP-1 agonist, has demonstrated promising results for both HbA1c reduction and weight reduction.(37,38) The SURPASS-1 (A study of tirzepatide [LY3298176] in participants with type 2 diabetes not controlled with diet and exercise alone; ClinicalTri…”
BackgroundMartin, W. P., Nair, M., Chuah, Y. H. D., Malmodin, D., Pedersen, A., Abrahamsson, S., Hutter, M., Abdelaal, M., Elliott, J. A., Fearon, N. M., et al. (2022) · Clinical Science · doi:10.1042/cs20220205 · Cited by 16
“…polypeptide (GIP) receptor agonist tirzepatide (5, 10, and 15 mg once weekly) vs semaglutide 1 mg once weekly as add-on therapy to metformin in patients with type 2 diabetes, reductions in body weight at week 40 were greater at all 3 evaluated doses of tirzepatide compared with semaglutide [26].”
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Blüher, M., Böhm, M., Brosius, F. C., Carr, R. D., Ceriello, A., Forst, T. M., Giorgino, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01481-0 · Cited by 17
“In addition, all participants received metformin (≥ 1500 mg per day) [39].”
BackgroundHeimburger, S. M. N., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K., & Christensen, M. B. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14545 · Cited by 13
“However, the relative role of GIP in these effects is uncertain and it should be noted that they occur alongside a negative energy balance and large weight loss.(20) Due to the complex interplay between GIP, GLP-1, insulin and glucagon, it is intriguing to what extent any lipolytic effect of GIP may be modified by fee…”
BackgroundWong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
“However, these drugs are challenged with long-term effectiveness, as most patients taking Semaglutide regain two-thirds of their lost weight after one year of withdrawal (Wilding et al. 2022).”
InfluentialLi, Y., Sun, W., Liu, H., & Ruan, X. Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101761 · Cited by 22
Peptide inhibitors: Breaking cancer code
Coburn, F., Nsereko, Y., Armstrong, A. J., & Musaimi, O. A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117961 · Cited by 13
Zamanian, N., Imani, H., Talebi, S., Rahimlou, M., Khosroshahi, R. A., & Mohammadi, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177966 · Cited by 19
CKDs at the Crossroads: From Failures to Future Therapies
Wehbe, F., Elliott, M., & Levin, A. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.050 · Cited by 17
Castaneda, R., Bechenati, D., Tama, E., Gutiérrez, R. D. J. R., Espinosa, M. A., Villamarin, J. L., Rajjo, T. I., Acosta, A. J., Faubion, S. S., SHUFELT, C. L., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(25)00145-1 · Cited by 17
Buse, J. B., BAJAJ, H. S., Dalskov, S., Donaldson, L., Duus, H. H. H., Fabricius, T. W., Haluzík, M., Lingvay, I., Pedersen, S. D., Pratley, R. E., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00125-7 · Cited by 22
Qi, Q. Y. D., Playfair, J., Brown, W. A., Burton, P. R., O’Brien, P. E., & Wentworth, J. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14992 · Cited by 13
“SGLT inhibitors are now recommended as a second-line glucoselowering medication after metformin for the treatment of type 2 diabetes(27) and recent innovation in GLP agonists has shown the newer weekly injectable formulations deliver vastly improved weight outcomes for individuals with type 2 diabetes who are overweig…”
BackgroundCurrent Weight Loss Medications: What Plastic Surgeons Should Know
Wirth, P. J., Shaffrey, E. C., Bay, C. C., & Rao, V. K. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad304 · Cited by 13
Tong, K., Yin, S., Yu, Y., Yang, X., Hu, G., Zhang, F., & Liu, Z. (2023) · Medicine · doi:10.1097/md.0000000000035488 · Cited by 18
“Frias 2018 is a short course of 26 weeks, while Frías 2021 [27] is a long course of 40 weeks.”
BackgroundResultInfluentialSuicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
Lau, D., & Gamble, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15459 · Cited by 13
Terenzi, D. C., Bakbak, E., Teoh, H., Krishnaraj, A., Puar, P., Rotstein, O. D., Cosentino, F., Goldenberg, R., Verma, S., & Hess, D. C. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvae016 · Cited by 15
Approach to the Patient With Type 2 Diabetes Requiring Add-On Medication
Baum, H. B. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae056 · Cited by 14
Akindehin, S., Liśkiewicz, A., Liśkiewicz, D., Bernecker, M., García‐Cáceres, C., Drucker, D. J., Finan, B., Grandl, G., Gutgesell, R. M., Hofmann, S. M., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101915 · Cited by 17
“GIPR:GLP-1R co-agonists improve body weight and glucose control with superior ef fi cacy relative to single GLP-1R agonists in preclinical [1,2] and clinical studies [3,4].”
First Report of Tirzepatide Hepatotoxicity with Jaundice
Fontana, R. J., Choi, E.-Y. K., Kaganove, J., & Dodson, A. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.025 · Cited by 9
Riedinger, C. J., Sakach, J. C., Maples, J. M., Fulton, J., Chippior, J., OʼDonnell, B., O’Malley, D. M., & Chambers, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.008 · Cited by 17
Weight Loss Therapies and Hypertension Benefits
Katsi, V. K., Manta, E., Fragoulis, C., & Tsioufis, K. P. (2024) · Biomedicines · doi:10.3390/biomedicines12102293 · Cited by 17
Block, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 16
Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran, M., Willis, J. R., Dalvi, N., Fokakis, Z. N., VIRKUS, S., & Hardaway, J. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf019 · Cited by 13
The emerging role of incretins and twincretins
Chow, E., & Chan, J. C. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00607-w · Cited by 16
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagonlike peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations.”
BackgroundLeveraging GPCR signaling in thermogenic fat to counteract metabolic diseases
Johansen, O. S., Ma, T., & Gerhart‐Hines, Z. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101474 · Cited by 15
“This potential impact of altering receptor internalization is exemplified by the GIP and GLP-1 dual agonist, tirzepatide, a powerful diabetes and obesity drug candidate [67].”
BackgroundAnti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 19
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221134127 · Cited by 13
Co-agonist therapeutics come of age for obesity
Tan, T. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00788-y · Cited by 13
Ala, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
“found that treatment with tirzepatide 5, 10, and 15 mg can lead to a greater weight loss, compared with semaglutide 1 mg.(126) The SURMOUNT-1 trial with 2539 nondiabetic participants with obesity or overweight measured the weight-lowering effect of one-weekly 5, 10, and 15 mg tirzepatide during 72 weeks.”
BackgroundBiology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Recent Advances Addressing the Challenges of Precision Dosing
Minichmayr, I. K., Mizuno, T., Goswami, S., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3365 · Cited by 13
Distinct Roles for Brain and Pancreas in Basal and Postprandial Glucose Homeostasis
Alonge, K. M., Porte, D., & Schwartz, M. W. (2023) · Diabetes · doi:10.2337/db22-0969 · Cited by 16
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13
“…efect has been proven by the recent SURPASS (efcacy and safety of a novel dual GIP and GLP-1 RA tirzepatide in patients with Type 2 diabetes) trials, where subcutaneous tirzepatide 5, 10 and 15 mg once weekly were compared to placebo, semaglutide, dulaglutide and basal insulin [20–25].”
Ma, J., Liu, M., Wang, R., Du, L., & Ji, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15446 · Cited by 12
Viljoen, A., Pantalone, K. M., Galindo, R. J., Cui, X., Huh, R., Hemmingway, A., Fernández Landó, L., & Patel, H. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01398-1 · Cited by 11
“for SURPASS-2 and SURPASS-3 have been published previously [2, 3].”
BackgroundMethodInfluentialSelf-citationTirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12
Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans
Liu, X., Lu, C. A., Shih, Y.-C. T., & Jiang, C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.29842 · Cited by 12
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 15
Tian, M.-Y., Yang, J.-Q., Hu, J.-C., Lü, S., & Ji, Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01448-9 · Cited by 19
“Among these, semaglutide speci fi cally addresses postprandial hyperglycemia and increases plasma insulin levels in T2DM patients [5].”
Feetham, C. H., Ai, M., Culotta, I., Costa, A., Hunter, J., Brown, R. A., Coşkun, T., Emmerson, P. J., D’Agostino, G., & Luckman, S. M. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102214 · Cited by 13
Weng, J., Alizadeh, M. A., & Friedman, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09344-w · Cited by 15
Khani, M., Afsahi, R., Nasab, A. E., Bi’aragh, S. H., Rasouli, K., Ahangar, M. H., Soltani, A., & Pourahmad, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01925-z · Cited by 23
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Al‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
Hsu, Y.-H., Liang, Y.-C., Chan, K.-C., Chou, Y.-H., Wu, H., & Ou, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112995 · Cited by 21
Roell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
“…dual GIP receptor (GIPR)/GLP-1R agonist tirzepatide has demonstrated reductions in body weight in people with overweight or obesity [6] and shown superior reductions in body weight and glycated hemoglobin (HbA1c) in people with T2D compared with the GLP-1R mono-agonist semaglutide [7,8].”
Berković, M. C., Bilić-Čurčić, I., Mrzljak, A., Canecki-Varžić, S., & Cigrovski, V. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1096 · Cited by 14
Naseralallah, L. M. A., & Aboujabal, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181074 · Cited by 17
“However, this was not associated with a significant reduction in total cholesterol, which could be attributed to the pronounced decrease of LDL in the GLP-1 group compared to tirzepatide group [27,29].”
BackgroundResultInfluentialPlaydon, M. C., Hardikar, S. S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023) · JNCI Monographs · doi:10.1093/jncimonographs/lgad003 · Cited by 14
Liarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 16
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Self-citationZeitler, P., Galindo, R. J., Davies, M. J., Bergman, B. K., Thieu, V. T., Nicolay, C., Allen, S., Heine, R. J., & Lee, C. J. (2024) · Diabetes Care · doi:10.2337/dc23-2356 · Cited by 14
Self-citationPeters, A. L., Buzzetti, R., Lee, C. J., Pavo, I. J., Liu, M., Karanikas, C. A., & Paik, J. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae372 · Cited by 18
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Pearce, L., Galán‐Arriola, C., Bell, R., Carr, R. D., Cunningham, J., Davidson, S. M., Ghosh, A. K., Giesz, S., Golforoush, P. A., Gourine, A. V., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01094-6 · Cited by 16
Kamrul-Hasan, A. B. M., Mondal, S., Dutta, D., Nagendra, L., Kabir, M. R., & Pappachan, J. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70032 · Cited by 23
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
Chen, M., Zhao, N., Shi, W., Xing, Y., Liu, S., Meng, X., Li, L., Zhang, H., Meng, Y., Xie, S., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf005 · Cited by 17
Trinh, H., Donovan, A., & McAdam‐Marx, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16343 · Cited by 18
Sen, A., Mohanraj, P. S., Laxmi, V., Ashique, S., Vasudevan, R., Aldahish, A. A., Velu, A., Das, A., Ehsan, I., Islam, A., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101305 · Cited by 17
“Summarise all ongoing clinical trials of novel therapies for T2DM are listed in Table 3 [67 e 71].”
Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis
Poljo, A., Reichl, J. J., Bürgi, S., Dirnberger, A. S., Schneider, R., Klasen, J. M., Billeter, A. T., Müller-Stich, B. P., Peterli, R., & Kraljević, M. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08136-5 · Cited by 16
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.